Tag Archives: Acute

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Severe Rhabdomyolysis in a Patient With Acute Influenza Infection

January 03, 2019 This article originally appeared here. Share this content: Rhabdomyolysis is characterized by breakdown of muscle tissue A recently published case report describes the case of a 29-year-old male patient with influenza-induced rhabdomyolysis and highlights the need to assess creatinine kinase (CK) levels of patients hospitalized with influenza. The patient, who had a… Read More »

FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia

FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia Print this page November 21, 2018 — The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75… Read More »

Which Drug Combination Works Best to Reduce Acute COPD Exacerbations?

November 20, 2018 Share this content: A higher blood eosinophil count was associated with a greater protective effect of ICS/LABA/LAMA against severe acute COPD exacerbations. A combination of inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) is possibly more effective than a LABA/LAMA combination or single long-acting bronchodilator therapy in reducing the risk for… Read More »